BRAF and melanoma: A recently initiated whole genome profiling study in melanoma in BRAF wild type patients31 and the NCI Molecular Analysis for Therapy Choice (MATCH) solid tumour study both illustrate the importance of having a multi-arm design which provide patients with potential access to a broad array of targeted therapies.